Side effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin colour, prickly heat, skin inflammation, skin loss or softening, stretch marks.
A topical glucocorticoid used in the treatment of eczema.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluocinonide. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocinonide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocinonide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocinonide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocinonide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocinonide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocinonide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluocinonide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Fluocinonide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinonide. |
| Pegaspargase | The serum concentration of Fluocinonide can be increased when it is combined with Pegaspargase. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocinonide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinonide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinonide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocinonide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocinonide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocinonide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinonide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocinonide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocinonide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocinonide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinonide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinonide. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocinonide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinonide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinonide. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluocinonide. |
| Cladribine | Fluocinonide may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinonide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluocinonide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocinonide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluocinonide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocinonide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocinonide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinonide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluocinonide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocinonide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinonide. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluocinonide. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocinonide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocinonide. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluocinonide. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Fluocinonide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocinonide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluocinonide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluocinonide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocinonide. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocinonide. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinonide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinonide. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinonide. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocinonide. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluocinonide. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fluocinonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Fluocinonide. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fluocinonide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocinonide. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Fluocinonide. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluocinonide. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fluocinonide. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocinonide. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocinonide. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Fluocinonide. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluocinonide. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluocinonide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluocinonide. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocinonide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluocinonide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocinonide. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluocinonide. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocinonide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocinonide. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluocinonide. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluocinonide. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fluocinonide. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocinonide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluocinonide. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocinonide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Fluocinonide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Capecitabine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Lomustine. |
| Budesonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Budesonide. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Dexamethasone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Nelarabine. |
| Abatacept | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Abatacept. |
| Corticotropin | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Cortisone acetate. |
| Paramethasone | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Paramethasone. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ciclesonide. |